Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Aug 152015
 

The Hygiology Post ®  has been presenting information about a company formerly called Senesco Technologies which recently merged and rebranded to Sevion Therapeutics that seems to have much potential to help many people. As a matter of disclosure : The author continues to be a current shareholder in the company.

The article published last month titled “Sevion Therapeutics Announces Establishment of a Biophysical Characterization Applications Lab” (https://www.seviontherapeutics.com/sevion-therapeutics-announces-establishment-of-a-biophysical-characterization-applications-lab/; obtained on 7-15-2015) began the following way:

 

“SAN DIEGO, CA – July 30, 2015 – Sevion Therapeutics, Inc. (‘Sevion’ or the ‘Company’) (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, has entered into an agreement with Malvern Instruments establishing a new biopharmaceutical applications laboratory in the heart of San Diego’s biotechnology cluster. The new laboratory will enable Sevion Therapeutics and customers of Malvern the experience and use Malvern’s range of specialist biophysical characterization systems in a working biopharmaceutical environment.

Under the terms of the agreement, several different Malvern analyzers will be installed in the applications laboratory. Initially this will include two microcalorimeters – the new MicroCal PEAQ-ITC and a MicroCal VP-Capillary DSC; a Viscotek TDAmax multi-detector size exclusion chromatography system; and a Zetasizer Nano ZSP for the measurement of size, electrophoretic mobility of proteins, zeta potential of nanoparticles and surfaces, and optionally the microrheology of protein and polymer solutions. Further protein characterization technologies from Malvern’s portfolio will be installed at future dates.

Dr Jim Graziano, Chief Technology Officer at Sevion Therapeutics is very pleased to be working with Malvern. ‘This venture provides a great opportunity for Sevion Therapeutics to access the latest biophysical measurement techniques and to help shape future developments. Malvern will provide extensive training and continuing support to our teams, and we will benefit both from having extended access to high value instrumentation and from Malvern’s technology and applications expertise. We’re especially excited to be adding differential scanning calorimetry to our armory and to being among the first to use the new MicroCal PEAQ-ITC system.’

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.  © 2015                                    The Hygiology Post ®